Corporate communications

May 29, 2023 The Company has products in various stages of testing and sales with more than 40 customers in 11 countries, with continued growth expected for the year. Q1 2023 revenue of $786,498; Adjusted EBITDA loss of $1.9 million. PharmaCielo continues to focus on

May 16, 2023 Represents PharmaCielo’s first shipment to South Africa, which has well-established export networks in the UK and Australia, and other potential markets, globally. TORONTO, Canada and RIONEGRO, Colombia (May 16, 2023) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the

May 1, 2023  During 2022, PharmaCielo made shipments to 23 clients in 9 countries, with continued growth expected for 2023. The Company’s measured investments in revenue-generating sales channels resulted in revenues of $5.3 million in 2022, almost three-times more than the $1.9 million reported in

April 19, 2023 Will bring unique high-THC Colombian strains owned by PharmaCielo to Europe for the first time. Combines PharmaCielo’s expertise in producing premium medicinal cannabis products, with CANNPRISMA’s conversion capabilities, to bring patients in Europe the highest quality high-THC flower product currently available in

February 8, 2023 PharmaCielo has received a purchase order for CBD Isolate as an API, which will be used by a large pharmaceutical company in Brazil (the “Customer”), for final testing. The Customer has already qualified PharmaCielo as a supplier of API – the Company

February 2, 2023 Steady progress against the efficiency plans initiated in mid-2021 with the transition to the current senior management team. Expects a reduction in its annualized fixed costs by approximately 25% compared to 2022 as a result of these ongoing efforts. The Company is

January 30, 2023 Ease Labs Pharma, a global pharmaceutical company headquartered in Brazil, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA) to launch its Canabidiol Ease Labs 100 mg/ml in Brazil beginning in January 2023, and PharmaCielo’s proprietary API was included as

December 5, 2022 Represents PharmaCielo’s first shipment to Africa. Morocco is pioneering the commercialization of cannabinoid products on the African continent and will be a growing market. The Company also announced that it has agreed to issue shares in settlement of certain interest payments and

November 22, 2022 TORONTO, Canada and RIONEGRO, Colombia (November 22, 2022) – PharmaCielo Ltd. (“PharmaCielo”or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced

October 31, 2022 In the first nine months of 2022, PharmaCielo has made shipments to 23 customers in nine countries, with continued growth expected for 2023. The Company has more than doubled Revenue to $3.8 million in the first nine months of 2022, compared to